Somite AI secures $47.5 million Series A to expand AI platform for cell therapy | CTech
Summary
Other participants include Max Levchins SciFi Ventures, The Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto, Pitango HealthTech, TechAviv, Harpoon Ventures, along with angel investor and former Chairman of Recursion, Dr. R. Martin Chavez.The company, which once called itself "the OpenAI of stem cell biology", has also welcomed its new CEO of Applications and Board Member Fidji Simo as an investor. Earlier investors included Texas Venture Partners, and this new round brings its total funding to roughly $60 million.Somite AI is developing DeltaStem, an AI-driven platform designed to improve the production of human cells for therapeutic use. The new funding will advance its capabilities and support programs targeting Type 1 Diabetes, orthopedic injuries, muscular diseases, and blood disorders.Were building the foundation model for the human cell, said Founder and CEO Dr. Micha Breakstone. By generating the worlds largest cell signaling dataset at 1000x the efficiency of current methods, were training DeltaStem to deliver protocols with unmatched purity, scalability, and reliability. "I think if you believe in AI and the exciting opportunities that it yields and the ability to make us more creative, smarter, more intelligent, more prosperous, I think the next frontier is actually not resigning ourselves to letting our own body deteriorate.